Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 5/20 | 0.54 |
| ▸ | GLA | P06280 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LDLR | P01130 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1285510 | 0.86 | KDM4E (0.54) | ACHEALDH1A1KDM4EGAAGLA | |
| SCHEMBL359701 | 0.84 | MAPT (0.56) | ALDH1A1KDM4EGAAHPGDLMNA | |
| SCHEMBL693859 | 0.84 | ACHE (0.56) | ACHEALDH1A1KDM4EGAAGLA | |
| SCHEMBL6018432 | 0.83 | KDM4E (0.57) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL27451728 | 0.83 | KDM4E (0.54) | ACHEALDH1A1KDM4EGAAGLA | |
| SCHEMBL10750857 | 0.82 | ALDH1A1 (0.50) | ACHEALDH1A1KDM4EGAAGLA | |
| SCHEMBL23417965 | 0.81 | KDM4E (0.52) | ACHEALDH1A1KDM4EGAAGLA | |
| SCHEMBL21464391 | 0.80 | KDM4E (0.61) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL3862443 | 0.79 | NPC1 (0.61) | ACHEALDH1A1KDM4EGAAGLA | |
| SCHEMBL4216870 | 0.79 | HPGD (0.54) | ALDH1A1GAAHPGDLMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2209790-B1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-17 | — | — | EP | disclosed |
| US-8263592-B2 | Equilibrative nucleoside transporter ENT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-04 | — | — | US | disclosed |
| EP-2209790-A2 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009062990-A2 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | SLC29A1, SLC29A2, SLC43A3 | ACHE 4760/4885ALDH1A1 516/4885KDM4E 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.